We are live on ! Find out more
MRVI icon

Maravai LifeSciences
MRVI

118 hedge funds and large institutions have $2.73B invested in Maravai LifeSciences in 2020 Q4 according to their latest regulatory filings, with 118 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1,490% more call options, than puts

Call options by funds: $5.21M | Put options by funds: $328K

100.83% more ownership

Funds ownership: 0% → 100.83% (+101%)

Holders
118
Holders Change
+118
Holders Change %
–
% of All Funds
2.09%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.09%
New
118
Increased
–
Reduced
–
Closed
–
Calls
$5.21M
Puts
$328K
Net Calls
+$4.89M
Net Calls Change
+$4.89M

Top Buyers

Rank Fund Capital Flow
1
DCP
D1 Capital Partners
New York
+$165M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$159M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$131M
4
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$118M
5
JP Morgan Chase
JP Morgan Chase
New York
+$115M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
26
Woodline Partners
California
$17.4M +$17.2M +619,217 New
Select Equity Group
27
Select Equity Group
New York
$17.1M +$16.9M +608,491 New
MWNA
28
Marshall Wace North America
New York
$17M +$16.9M +607,554 New
CCA
29
Canyon Capital Advisors
Texas
$16.8M +$16.7M +600,000 New
OAM
30
Ophir Asset Management
Australia
$13.9M +$13.8M +494,971 New
Point72 Asset Management
31
Point72 Asset Management
Connecticut
$13.9M +$13.8M +493,883 New
FLAM
32
First Light Asset Management
Minnesota
$10.3M +$10.3M +368,200 New
Marshall Wace
33
Marshall Wace
United Kingdom
$10.2M +$10.1M +362,980 New
MIM
34
Monashee Investment Management
Massachusetts
$10.1M +$10M +360,000 New
PA
35
Perceptive Advisors
New York
$9.82M +$9.75M +350,000 New
PGM
36
Parian Global Management
New York
$8.84M +$8.77M +315,000 New
HF
37
HRT Financial
New York
$8.57M +$8.5M +305,395 New
Squarepoint
38
Squarepoint
New York
$8.54M +$8.48M +304,479 New
Adage Capital Partners
39
Adage Capital Partners
Massachusetts
$8.41M +$8.35M +300,000 New
Two Sigma Investments
40
Two Sigma Investments
New York
$8.08M +$8.03M +288,198 New
Jennison Associates
41
Jennison Associates
New York
$7.44M +$7.39M +265,386 New
PVI
42
Pura Vida Investments
New York
$7.21M +$7.16M +257,000 New
BPIM
43
Brant Point Investment Management
New York
$6.71M +$6.66M +239,175 New
DCM
44
Driehaus Capital Management
Illinois
$6.29M +$6.25M +224,299 New
LCM
45
Laurion Capital Management
New York
$4.91M +$4.87M +175,000 New
Tudor Investment Corp
46
Tudor Investment Corp
Connecticut
$4.9M +$4.87M +174,735 New
ACG
47
Anchorage Capital Group
New York
$4.21M +$4.18M +150,000 New
Lord, Abbett & Co
48
Lord, Abbett & Co
New Jersey
$4.17M +$4.14M +148,748 New
CCM
49
Cinctive Capital Management
New York
$3.48M +$3.45M +124,001 New
PHP
50
Parkman Healthcare Partners
Connecticut
$3.09M +$3.07M +110,276 New
1
2
3 4 5

MRVI Hedge Fund Activity: Q4 2020 in Review

118 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q4 2020, worth a combined $2.73B.

Buyers outnumbered sellers: 118 funds opened new MRVI positions and 0 closed out — a net gain of 118 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was D1 Capital Partners, opening a new position worth an estimated $165M.

  • 118 institutional investors held Maravai LifeSciences (MRVI) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $2.73B of Maravai LifeSciences stock for Q4 2020.
  • 118 funds opened new Maravai LifeSciences positions in Q4 2020 and 0 closed out, a net change of +118 holders.
  • The largest Maravai LifeSciences buyer in Q4 2020 was D1 Capital Partners, an estimated $165M added.

Based on aggregated 13F filings for Q4 2020.